

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)



(10) International Publication Number
WO 2022/233956 A1

(51) International Patent Classification:

C07K 16/30 (2006.01) A61K 39/00 (2006.01)
C07K 14/47 (2006.01) A61P 35/00 (2006.01)
C07K 14/725 (2006.01)

(21) International Application Number:

PCT/EP2022/062017

(22) International Filing Date:

04 May 2022 (04.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21172351.5 05 May 2021 (05.05.2021) EP
63/184,689 05 May 2021 (05.05.2021) US

(71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH
[DE/DE]; Paul-Ehrlich-Str. 15, 72076 Tübingen (DE).

(72) Inventors: PSZOLLA, Gabriele; Schwabstrasse 68, 72076 Tübingen (DE). HOFMANN, Martin; c/o Immatrics Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen (DE). HUTT, Meike; c/o Immatrics Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen (DE). BUNK, Sebastian; c/o Immatrics Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen (DE). UNVERDORBEN, Felix; c/o Immatrics Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen (DE). SCHWÖBEL, Frank; c/o Immatrics Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen (DE). MAURER, Dominik; c/o Immatrics Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen (DE). JAWORSKI, Maike; c/o Immatrics Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen (DE). WAGNER, Claudia; c/o Immatrics Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen (DE). SCHWÖRER, Florian; c/o Immatrics Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen (DE). SCHUSTER, Heiko; c/o Immatrics Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen (DE).

(74) Agent: ZWICKER, Jörk; Zwicker Schnappauf & Partner Patentanwälte PartG mbB, Hansastr. 32, 80686 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2022/233956 A1

(54) Title: ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME

(57) Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.